Ausgabe 4/2016
Inhalt (13 Artikel)
Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: ‘Game Over’?
Alessandra Modena, Francesco Massari, Chiara Ciccarese, Matteo Brunelli, Matteo Santoni, Rodolfo Montironi, Guido Martignoni, Giampaolo Tortora
The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development
Jun Gong, Gauri Kelekar, James Shen, John Shen, Sukhpreet Kaur, Monica Mita
Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints
Maria Alsina, Markus Moehler, Cinta Hierro, Raquel Guardeño, Josep Tabernero
Ramucirumab Clinical Development: an Emerging Role in Gastrointestinal Tumors
Amparo Sanchez-Gastaldo, Reyes Gonzalez-Exposito, Rocío Garcia-Carbonero
Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC)
Mario Scartozzi, Loic Vincent, Marielle Chiron, Stefano Cascinu
Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts
J. Rolff, M. Becker, J. Merk, J. Hoffmann, I. Fichtner
French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends
Christos Chouaid, Isabelle Borget, Eric Braun, Marie-Laure Bazil, Dominique Schaetz, Cécile Rémuzat, Mondher Toumi
Novel TNF-related Apoptotic-inducing Ligand-based Immunotoxin for Therapeutic Targeting of CD25 Positive Leukemia
Jayaprakasam Madhumathi, Surapally Sridevi, Rama Shanker Verma
Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy
E. Bondon-Guitton, S. Combret, M. C. Pérault-Pochat, M. Stève-Dumont, H. Bagheri, F. Huguet, F. Despas, A. Pathak, J. L. Montastruc
Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab
Jeremy W. Vandiver, Zachary Singer, Cara Harshberger
Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report
Andrew J. Dooley, Avinash Gupta, Mark R. Middleton
Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
Sandrine Faivre, Armand de Gramont, Eric Raymond